PatentsGlobal
BioCorRx Reports Q3 2026 Form 10-Q Filing, Advances Clinical Trials and Secures New Patent for Naltrexone Implant
BioCorRx Inc. has filed its Q3 2026 Form 10-Q, detailing significant progress in commercial, clinical, intellectual property, and governance areas. The company established new National Drug Codes for LUCEMYRA® and its authorized generic ahead of a year-end commercial transition. It also launched a Phase 1 clinical tri…
Tuesday, November 17, 2026